2026 FDA Peptide Reclassification Purefico Medspa and Therapy The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 (Body Protection Compound 157) Peptide for Tissue Repair & R ELITE BIO COMPOUNDS FDA Peptide Reclassification 2026: What Researchers Want FDA mulls compounding for peptides previously flagged over safety risks BioSpace The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step